DETAK by Brawijaya University Researchers detects Heart Disease Early and Accurately

Malang, East Java, Indonesia, Nov 27, 2020 – (ACN Newswire) – Researchers from the Brawijaya University (UB) Medical School in Malang, East Java have developed DETAK, a smartphone application for patients with heart disease. The app works on an AI (artificial intelligence) algorithm, to provide early and accurate detection of heart disease, or acute coronary syndrome, and prevent delays in proper diagnose and treatment.

Acute coronary syndrome describes a host of conditions linked to the sudden, reduced flow of blood to the heart. One such condition is a myocardial infarction, or heart attack, in which cell death results and can lead to damaged or destroyed heart tissue. DETAK was designed to prevent these types of occurrences with early discovery.

"Apart from functioning as an early detection tool encouraging patients to seek treatment, DETAK serves to remind heart disease patients to take their medication and undergo medical checkups regularly," noted Mohammad Saifur Rohman, the lead researcher of cardiovascular study at the UB Medical School. The application also offers informative articles on heart disease and advice for maintaining a healthy heart.

Rohman drew attention to the importance of the early detection service in the application, since delay in the detection of heart disease is a main causal factors in the high number of heart attack cases resulting in death, citing data from the Dr. Saiful Anwar Hospital in Malang. He attributed this delay in detection mostly to a lack of knowledge and awareness of the symptoms of acute coronary syndrome.

For early detection of the ailment, patients using the DETAK app answer several questions related to chest pain they experience and will be notified on where to go to seek help. The app will direct users with high risk of acute coronary syndrome to hospitals with cardiologists on duty, while those with low risk of acute coronary syndrome will be directed to visit nearby health facilities with general practitioners on duty.

The DETAK application has already received the Indonesian Museum of Records (MURI) award, and will soon cover health facilities across Indonesia, with data collection in collaboration with the Indonesian Cardiologist Association (PERKI), Indonesian Medical Association (IDI) and other related facilities.

For further information, contact:
Universitas Brawijaya (UB) Public Relations
www.ub.ac.id and www.prasetya.ub.ac.id.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

DETAK by Brawijaya University Researchers detects Heart Disease Early and Accurately

Brawijaya University develops GAD65 Rapid Test Diabetes Screening Kit

Malang, East Java, Indonesia, Nov 25, 2020 – (ACN Newswire) – Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes. The Bioscience Rapid Test GAD65, developed by aresearch team led by Prof. Dr. Aulanni'am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus, before measures and treatment are determined.

The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).

Diabetes is a global health threat which can lead to complications that impact the quality of human life as well as substantially add to health costs for families and countries. Its increasing prevalence has raised concerns globally and prompted prevention efforts. Detecting and managing the condition through appropriate therapy is crucial for preventing deterioration in the condition of people suffering from the metabolic disease.

The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero). The preparation and production of the kit has involved various levels of research and testing, based on the consensus and regulations set by the World Health Organization (WHO) and the Indonesian Health Ministry.

The screening kit, which has a medical device distribution permit and meets the certification requirements for good medical device manufacturing from the Indonesian Ministry of Health, is ready to be produced and widely distributed and has been introduced to potential consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines, and Malaysia.

As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and P00201910578, 2019-Registered).

For further information, please contact:
Prof Dr. Aulanni'am, drh., DES
+62 812-3317-600
Public Relations,
Universitas Brawijaya
www.ub.ac.id
www.prasetya.ub.ac.id

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

SinoMab Commenced Construction of its China Headquarters

HONG KONG, Nov 23, 2020 – (ACN Newswire) – SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that SinoLink Pharma (Suzhou) Limited ("SinoLink Pharma"), a wholly-owned subsidiary of the Company, held a commencement ceremony of its new campus on 20 November in Suzhou Industrial Park, marking the official commencement of construction of SinoMab's China headquarters.

SinoMab China headquarters – SinoLink Pharma new campus commencement ceremony: Dr. Shui On Leung, the Executive Director, Chairman and CEO of SinoMab (right 3rd); Mr. Jing Qiang, the Executive Director and President of SinoMab (left 3rd)

SinoMab China headquarters – SinoLink Pharma new campus preview

SinoMab plans to invest 1 billion on the construction of the new campus of SinoLink Pharma in the next 2 years, which will become the Company's China headquarters. The total floor area amounted to 70,000 sq.m., including manufacturing shop, pilot plant, R&D center, quality inspection center, clinical study center, administration building, and biological reaction workshop with a capacity of 38,000 litres. The civil construction is expected to be completed by the end of 2022. Upon the completion of construction, the new campus will be able to produce 2.5 to 3.0 million bottles of mAb injection per year, representing a relatively high level in the industry.

SinoMab possesses an extensive drug candidate pipeline based on mAb, targeting on the treatments of various immunological diseases. The Company's flagship product, SM03, a potential global first-in-target anti-CD22 mAb for the treatment of Rheumatoid arthritis (RA), is currently in phase III clinical trials in China and expected to be commercialized by the end of 2021. One of the Company's key product, SN1011, has received the Investigational New Drug (IND) approval from the National Medical Products Administration of China. The IND approval would enable the Company to conduct comprehensive clinical development programs for the treatment of systemic lupus erythematosus (SLE) in China. And the Company plans to initiate the phase I clinical study in China in the near future.

Dr. Shui On Leung, the Executive Director, Chairman and Chief Executive Officer of SinoMab, said on the commencement ceremony: "SinoLink Pharma is SinoMab's headquarters of R&D, manufacturing, marketing and operation and the industrialization base in mainland China. The commencement of construction of the new campus marks the new start and journey of the Company's next 'Five Years' Plan'. As the smooth progress of the clinical trials of SM03, our flagship product, and SN1011 entering clinical stage, the Suzhou new campus will provide a platform and guarantee for our drug candidates' R&D progress and commercialization in the Chinese market acting as our headquarters in mainland China, R&D center and the most important manufacturing base. Looking forward, we will insist in independent innovation, accelerating R&D and commercialization and strengthening global cooperation and technical innovation based on our existed drug candidates and R&D capability, to become an important force in the global healthcare industry."

About SinoMab BioScience Limited
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Antengene Corporation Limited Successfully Listed on Main Board of SEHK

HONG KONG, Nov 20, 2020 – (ACN Newswire) – Antengene Corporation Limited ("Antengene" or the "Company", together with its subsidiaries, the "Group", stock code: 6996.HK), a clinical-stage biopharmaceutical company with integrated drug discovery, clinical development, anchored in Asia-Pacific (APAC) with a global layout, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.

Antengene's listing ceremony in Shanghai:
Dr. Jay Mei, M.D., Ph.D., founder, Chairman and CEO (Left); Mr. Yiteng Liu, M.Sc., Chief Operating Officer (Right)

The total number of offer shares under the Global Offering amounts to 154,153,500 shares, with the final offer price determined at HK$18.08 per offer share. The net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and expenses paid and payable by the Company in connection with the Global Offering, are estimated to be approximately HK$2,635.9 million. The Hong Kong offer shares initially offered under the Hong Kong Public Offering have received satisfactory response, where the total number of valid applications amounted to approximately 264.76 times of the total number of Hong Kong offer shares initially available for subscription under the Hong Kong Public Offering. The offer shares initially offered under the International Offering have also been over-subscribed by approximately 13.5 times. Due to the heavy over-subscription under the Hong Kong Public Offering, the Company has adopted the claw back mechanism, through which part of the shares have been reallocated from the International Offering to the Hong Kong Public Offering. The final numbers of Hong Kong offer shares and International offer shares are respectively 77,077,000 and 77,076,500, each representing approximately 50% of the total number of the offer shares initially available under the Global Offering before any exercise of the over-allotment option.

Antengene, which focuses on innovative oncology medicines, adopts a differentiated combinatory and complementary R&D approach to discover, develop and commercialize global first-in-class, only-in-class and/or best-in-class therapies, in order to fully unlock their therapeutic potential. As of the latest practicable date, the Company had built a highly selective pipeline of 12 drug assets focused on oncology, in which one of the Company's core products, ATG-010 (selinexor) or XPOVIO (selinexor), is a first-in-class and only-in-class selective inhibitor of nuclear export (SINE) compound that inhibits the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus and selective induction of apoptosis in cancer cells. Currently, the Company has initiated two Phase II registrational clinical trials for R/R MM and R/R DLBCL and will leverage the data from the clinical trials carried out by Karyopharm (a global pharmaceutical company listed on NASDAQ) to submit the new drug application (NDA) for ATG-010 (selinexor) by 2021 directly in certain APAC countries or territories where NDA approval may be obtained without additional clinical trials, including Australia, Singapore, Hong Kong, South Korea, Taiwan and Thailand.

Dr. Jay Mei, M.D., Ph.D., founder of Antengene, has over 25 years of experience in clinical research and development of oncology therapeutics globally, focusing on the clinical R&D of oncology drugs in the United States and China. Other management members also have strong proven track records in the research, clinical development and commercialization of drugs around the globe as well as in financing and investments. Since Antengene's establishment, with its premier and experienced management team, it has received supports from industry-leading investors, including strategic investors such as Celgene, WuXi AppTec and Tigermed, and financial investors such as Fidelity, Blackrock, GIC, Hillhouse, Boyu Capital, FountainVest Partners and Qiming Venture Partners. Meanwhile, Fidelity, GIC, Blackrock, Boyu Capital, Cormorant, Hillhouse, Sequoia Capital China Growth, CRF Investment, Laurion Capital Master Fund and Octagon Investments are also the cornerstone investors in the Company's Global Offering.

Dr. Jay Mei, M.D., Ph.D., founder, Chairman and CEO of Antengene said, "Today marked a milestone in Antengene's development. Antengene's successful debut in the Hong Kong stock market shows global investors' profound recognition for our strategic model, growth potential, management team and product pipeline. We are so proud of it and would like to express our gratitude to investors for their trust in and support to Antengene. Setting off from a new starting point, we will seize the historical opportunity in the global novel drug development. By adopting the differentiated development approach and grasping the hot spots at the cutting edge of R&D, we will persevere in discovering, developing and commercializing novel oncology therapies with novel mechanisms so as to address unmet clinical needs in APAC and other parts of the world."

About Antengene Corporation Limited
Antengene Corporation Limited is a clinical-stage APAC biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide novel anti-cancer drugs to patients in APAC and around the world. Since its inception, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 9 IND approvals and has 9 ongoing cross-regional clinical trials in the APAC region. At Antengene, we focus on developing drug candidates with novel targets or MoAs and first-in-class potential to address significant unmet medical needs. The vision of Antengene is to "Treat Patients Beyond Borders" through research, development and commercialization of first-in-class/best-in-class therapeutics.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002

HONG KONG, Nov 12, 2020 – (ACN Newswire) – Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. ("Zhaoke Hong Kong") is pleased to announce today that the first patient has completed three year enrollment in the Phase III CHAMP (Childhood Atropine for Myopia Progression) study carried out by its partner, Nevakar Inc. ("Nevakar"). The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound, NVK-002, to slow the progression of myopia in children. NVK-002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages three to seventeen.

NVK-002 is a novel and first-to-market pharmacologic treatment for slowing the progression of myopia in children. It is currently under clinical evaluation in the CHAMP study and has entered Phase 3 clinical trial in the US and Europe. The CHAMP trial follows ground-breaking studies conducted in Asia that concluded that low doses of atropine could be used to slow the progression of myopia in children. CHAMP is a 576 subject, randomized, placebo-controlled, double-masked study evaluating the effects of NVK-002 on myopia progression in children. The study duration is three years, after which enrolled patients are re-randomized for a fourth year of follow-up. With this milestone, the trial remains on-track for a three-year data readout in 2022.

On October 19, 2020, Zhaoke Hong Kong and Nevakar entered into an exclusive licensing agreement for the development and commercialization of Nevakar's NVK-002 in Greater China (The People's Republic of China ("PRC"), Hong Kong SAR, Macau SAR and Taiwan), South Korea and the Southeast Asian territories.*

Under the terms of the agreement, Zhaoke Hong Kong will develop and obtain regulatory approval for NVK-002 in the contractual territory as well as manufacture, launch, distribute, and support the commercialization of the product.

Zhaoke Hong Kong is a wholly owned subsidiary of Zhaoke Ophthalmology Limited, which has a strong foundation in ophthalmology and is an emerging leader in the integrated eye care field in the PRC and Asia. Currently, there are over 100 million children with myopia in China.

"Despite the many challenges posed by the COVID-19 pandemic, Nevakar has achieved this important milestone in the development of our lead compound, NVK-002, which, if approved, would represent an innovative, first-to-market pharmacologic treatment for myopia in children," stated Navneet Puri, PhD, Founder, Chairman and Chief Executive Officer of Nevakar.

"Nevakar's NVK-002 is the most advanced innovative atropine product in development for the treatment of myopia. In-licensing of NVK-002 not only puts Zhaoke Ophthalmology in the leading position in the fight against myopia in China, Southeast Asia and South Korea but also strengthens its already comprehensive pipeline in ophthalmology," said Dr. Benjamin Li, Ph.D., Chairman and Chief Executive Officer of Zhaoke Ophthalmology Limited.

*Southeast Asian territories include: Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, and Vietnam.

About Nevakar Inc.

Nevakar Inc. is growing as a fully integrated privately held, late-stage biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Founded in 2015, and headquartered in Bridgewater, New Jersey, the Company is focused on developing and commercializing innovative products to address unmet medical needs, thereby improving patient care and quality of life. Nevakar utilizes the 505(b)(2) regulatory pathway, along with its proven expertise in the development of novel and proprietary sterile pharmaceutical products to identify, develop and obtain regulatory approval for its products. Additional information is available at www.nevakar.com.

About Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited

Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. is a wholly owned subsidiary of Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology"), which specializes in the development, manufacturing and marketing of ophthalmic drugs. It has built a state-of-the-art development and production facility in Nansha, Guangzhou through its 100% subsidiary Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited. The facility supports the in-house development and future commercialization of more than twenty proprietary products and difficult to manufacture generics (ranging from pre-clinical to registration stage) for the Chinese and ASEAN markets. It is currently the only modern facility in China that is recognized as being designed and built for ophthalmic drugs according to all applicable standards, namely China National Medical Products Administration, Pharmaceutical Inspection Co-operation Scheme (PIC/S), European Medicines Evaluation Agency, Japan Pharmaceutical and Food Safety Bureau and U.S. Food and Drug Administration (FDA). Zhaoke Ophthalmology portfolio is diversified in having both small molecules and biologics, and having both novel and generic medicines, covering different ophthalmic indications from dry eye, glaucoma, wAMD, diabetic retinopathy to corneal and inflammatory diseases.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine

Vancouver, BC, Nov 11, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. Previous interim data from the study showed it possessed an excellent emerging tolerability profile with no noteworthy clinical observations or observed toxicities in the mice. When the study concluded after 6 weeks, the excellent safety and tolerability profile was maintained.

The preclinical study, which began in September 2020 and was conducted by leading independent contract research organization ("CRO") Charles River Laboratories, Inc. under contract with BioVaxys, evaluated the anti-virus immune response elicited by BVX-0320 in a controlled murine model by measuring the development of antibodies to the protein that binds the virus to human cells. Following two injections of BVX-0320 together with the immunological adjuvant, QS21, to 28 mice at four dosage levels, 96.4% developed positive antibody responses detected at week 6. As expected, prior to administering BVX-0320, all animals were antibody-negative, except for one mouse that had a borderline response. Importantly, mice that received the QS21 adjuvant without BVX-0320 developed no antibody responses.

Kenneth Kovan, co-founder, President and Chief Operating Officer of BioVaxys spoke to the results, "As the early data shows that BVX-0320 stimulates an antibody response to the SARS2 s-spike protein, we would expect to see a similar response against live virus infection. Although that work remains to be done, this new data is pivotal at this stage of development of our vaccine."

BioVaxys and Charles River Laboratories continue to analyze the experimental data to determine the antibody levels induced by each dose and to measure the T cell responses. The latter consists of stimulating T cells obtained from the same mice with viral peptides and measuring the degree of T cell activation using the established analytical method of flow cytometry and the production of cytokines, including IL2 and gamma interferon. In a separate study, the mouse sera (collected from the test animals) will be tested for ability to inactivate live SARS-Cov-2 virus. Results are anticipated within the next month.

Upon completion of the data analysis, BioVaxys anticipates taking further steps to pursue regulatory approval for a Phase I study of its BVX-0320 vaccine candidate in humans.

James Passin, the CEO of BioVaxys, stated, "Although still early, we are very encouraged that the emerging profile for BVX-0320 is a relatively uncomplicated manufacturing process and a temperature-stable vaccine suitable for broad distribution, which lends itself to address a pandemic." Passin further stated, "We hope to leverage this data to accelerate ongoing discussions with potential pharmaceutical partners on the development of new viral antigen vaccine candidates based on our haptenized viral protein vaccine platform technology."

BioVaxys' product pipeline includes BVX-0918A, an IND-stage haptenized cancer cell vaccine for treating late stage ovarian cancer. In Phase I and Phase II clinical studies previously conducted by BioVaxys, co-founder and Chief Medical Officer, Dr. David Berd, using an earlier generation of the BioVaxys cancer vaccine on nearly 500 patients with melanoma or ovarian cancer, the haptenized cell platform showed significant clinical promise.

Dr. Berd commented that, "A post-SARS2 infection T cell response appears to be a defining characteristic following recovery in COVID-19 patients. As we have observed significant T cell responses in previous studies following vaccination with haptenized proteins in cancer patients, our belief is that we will see the same clinical results with our haptenized vaccine platform in in viral diseases."

BioVaxys has developed its vaccine technology platforms based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. The process of haptenization "teaches" a patient's immune system to recognize and make target proteins more 'visible' as foreign, thereby stimulating an immune response.

For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FSE: 5LB).

ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054

Media Contacts
Andrea Vuturo
+1 508 301 3774
biovaxys@dittopr.co

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVayxs' vaccines will not prove to be effective and/or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67931

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

With Two Potential First-in-class Innovative Drugs’ Commercialization around the Corner, RemeGen is Expected to Explode upon Listing

HONG KONG, Nov 6, 2020 – (ACN Newswire) – According to Bloomberg, recent years have seen the strong performance of biopharmaceutical enterprises in Hong Kong stock market. Bonnie Chan, Head of Listing of HKEX, said at the HKEX Biotech Summit on 1st September this year that 20 pre-revenue biotechnology companies had been listed in Hong Kong by then, raising a total of HK$48 billion in IPOs, and a total of HK$46 billion in post-IPO financing. The public offerings of BeiGene, Innovent Biologics and Junshi Biosciences have all expanded multiple times upon their IPO in their market value. With the listing of RemeGen next Monday, Hong Kong is to welcome another biotech superstar.

Popular subscription and substantial room for rise in market value post IPO

The public offering of Ant Group last week froze a large amount of capital, posing pressure on other pre-listing companies. However, offering from RemeGen still gained great traction, with its institutional books hundreds multiple times covered and retail book over 50-time subscription in pool A and hundreds of times in pool B. With the sudden halt of Ant Group's IPO and hundreds of billions of funds being refunded to Hong Kong investors, it is expected that RemeGen would become a new hit of the market.

Due to the over-subscription and the 'claw-back' mechanism, the shares distributed to institutional investors were extremely tight. Nevertheless, the structure of the institutional book was extremely strong. Majority of the investors areglobally renowned long-only funds, leading healthcare corporates in China, healthcare specialists as well as well-known tycoons and family offices from both Hong Kong and China. After the listing of RemeGen, these investors will continue to increase their position given the limited amount of allocation they received during the IPO due to the "claw-back" mechanism mentioned above. This will provide a margin of safety for the company's post-market performance.

The estimated value of RemeGen after IPO is expected to be approximately HK$25 billion, comparing with BeiGene's current market cap of ~HK$200 billion, Innovent's current market cap of ~HK$80 billion and Junshi Biosciences's current market cap of ~HK$40 billion. RemeGen has substantial room to continue to climb after the IPO. It is highly likely that the market will witness a strong post-market performance of RemeGen, which can fully represent its market value.

Star management team to ensure that the innovative drugs will receive marketing approval and enter the market within the next 3-8 months

Established in 2008, RemeGen has a management team featuring extensive industry experience and professional expertise. Dr. Fang Jianmin, the co-founder, CEO and CSO of RemeGen, is one of the few corporate founders in the domestic biopharmaceutical industry with a successful track record of progressing novel biological drugs from discovery through development and commercialization. Dr. Fang is the original inventor of Conbercept, which is a well-known biologic drug and was ranked top ten in terms of revenue in China last year. At the same time, he is also a member of scientific Expert Committee of the Special Major Project for Technologies of Innovative Manufacturing of Major New Drugs. Dr. Fang has more than 20 years of extensive experience in biopharmaceutical R&D and owns more than 40 patents for pharmaceutical invention.

Dr. He Ruyi, the CMO of RemeGen, is one of the most authoritative experts in China in the areas of clinical development and global regulatory regimes for medical products. With nearly 20 years of experience working at the FDA in the U.S., Dr. He has led multiple important policy initiatives during his tenure as Chief Scientist at the Center for Drug Evaluation (CDE) of the NMPA. In addition, Dr. He is an important committee member in the biotech expert committee at the Hong Kong Stock Exchange. Under Dr. He's leadership, RemeGen is in the process of receiving market approval for two of its leading innovative drugs within the next 3-8 months.

What is worth mentioning is that among the pre-revenue biotech companies in the Hong Kong market, RemeGen is, other than BeiGene, the only enterprise with two innovative drugs, namely Telitacicept and Disitamab vedotin, which are both expected to receive marketing approval within the next 3-8 months. Telitacicept is mainly used for the treatment of B cell-mediated autoimmune diseases. As there is no effective cure for such diseases, Telitacicept is expected to be the best-in-class therapy in global SLE market which ever-growing with largely untapped potential. Disitamab vedotin is a kind of antibody-drug conjugates (ADC) which is mainly used for the treatment of common cancers. ADC is the branch of oncology therapeutics which attracts the most attention and investment given its therapeutic potential. Disitamab vedotin has the potential to become the first-to-market ADC in China and is well-positioned to capture large demand of the market.

In addition, RemeGen has global development and commercialization rights to the above candidates and will expand its businesses globally in the years to come. The dealings of RemeGen will officially commence on the Main Board of the Stock Exchange on 9 November. Given that the company has two innovative drugs about to reach the commercialization stage with more room for growth in the future, RemeGen is definitely a high-quality target of great investment value.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Captiva Verde Comprehensive Update

Coquitlam, British Columbia, Nov 2, 2020 – (ACN Newswire) – Captiva Verde Land Corp. (CSE: PWR) (OTC: CPIVF) (the "Company"), is pleased to report an update on all of our major operating business segments plus our recommendation of a financial newsletter written by an award winning portfolio manager.

Financial Newsletter – Grit Capital

Captiva Verde sponsored an investor event in Las Vegas in December 2019 with Grit Capital. Beginning November 1, 2020, Grit Capital has launched a very efficient and easy to read, fun, exceedingly informative, and highly impactful Investment Newsletter that covers emerging trends, themes and investment ideas which is based on where big money and momentum is moving in the market, long before the general investing public studies the available information. The newsletter is written by Genevieve Roch-Decter, CFA, a former $100 Million+ small cap portfolio manager who's fund was ranked #1 for 3 of the 7 years she ran it (as ranked by Globe & Mail – GlobeFunds). We strongly recommend all of our shareholders and all interested friends and family to subscribe to the free newsletter at https://gritcapital.substack.com

Solargram Farms ("SGF")

SGF just completed its 1st year harvest in Renauds Mills NB, growing 13,000 plants over approximately 20 acres within its Health Canada 50 acre licensed outdoor cannabis cultivation footprint (total 130 acres land package for future expansion). SGF averaged 1 person per acre from the grow team to grow the first year harvest and made approximately 95% of the operating costs, variable costs.

SGF obtained its cultivation license on June 26th in the middle of the Covid19 Pandemic and successfully planted, nurtured, and subsequently finished the fall harvest last Sunday. SGF has harvested approximately 16,000kg of cannabis which will yield approximately 3800kg of dried cannabis. SGF has purposely planned produced approximately 500 to 600kg of cured dried flower within the larger harvested product this year, that is destined for bulk sales to customers over the next 4 to 6 weeks that will commence the monetization of sales. This initial planned sales represents less than 15% of the harvest volume that will generate over $1.6 million in sales that is expected to cover all of the 2021 forecasted operating expenses before commencing producing the much higher valued, oil extracted based cannabis products that have been requested by our customers.

The balance of the harvested product has now been milled and will be sent to the extraction partner for oil processing as soon as SGF's obtains the Health Canada sales and processing license which is expected within six weeks. This processed oil extract will allow SGF to produce planned scheduled products that will satisfy the customer's request for product. The first year estimated sales will be in excess of $15,000,000 starting early 2021 at a forecast 60-70% gross margin. The two main harvested genetics which comprises 85% of the crop has initially tested 19%-22% THC which is a major win for such a large outdoor grown crop. Further broader representative sample testing will be done once the harvest is completely dried within another week which we expect will be within the same relevant range previously obtained.

SGF's has commenced growing the 2021 season mothers and clones and expects to produce 20,000 plants with very low additional capital costs, expecting that will in fact more than double the 2021 production yield and sales on the same 2020 production footprint.

We remain a debt free company and, as a result, will be able to provide shareholders with a significant return on investment once sales and profitability materializes in 2021.

Sage Ranch

The final Planning Commission approval looks like it will be on December 9. After that date we wait 45 days and we can begin construction. We have over 200 families on the waiting list to purchase homes and we have engaged Keller Williams – Paul Morris Forward Living to sell our remaining units to the 1 million people who live within a 40 minute drive and a further 25 million people who live within a 2 hour drive of the subdivision.

We expect the entire 1,000 units ($400 Million) to sell out and this upcoming Planning Commission approval is a game changing event. Entry Level Real Estate prices have soared and demand is very high as California is short 2.4 million entry level homes.

Esmeralda

Our new pharmaceutical manufacturing plant structure is completed. We have 3 more weeks of electrical, plumbing and finishing touches. We have generated an equipment list and the final step is purchasing and installing the manufacturing equipment. We expect this completed by year end which is to fulfil our USD $142 Million yearly sales contract with the Health Care Workers Union.

Miss Envy

We have designed some product for Asia and getting very positive feedback on the product quality. Working towards the next steps of larger acceptance by various groups in Asia. Miss Envy is providing both Mexico (Esmeralda) and Solargram with product strategies and assistance in preparing for revenue sales in both Canada and Mexico.

On Behalf of the Board of Directors
"Jeffrey Ciachurski"
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca

Cautionary Note Regarding Forward-Looking Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67309

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity

Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19.

The BioVaxys method is based on measuring an immune response in a human showing no signs or symptoms of an active SARS-CoV-2 infection by administering a skin test of a subunit of the SARS-CoV-2 S-protein. Using Delayed Type Hypersensitivity[1] ("DTH"), a method which is known to demonstrate prior exposure and T cell immunity to tuberculosis[2], the immune system causes an inflammatory response that develops 24 to 72 hours after exposure. This type of immune response involves mainly T-cells rather than antibodies, which are made by B-cells.

If ultimately successful, the diagnostic is intended to provide a low-cost, easy-to-administer, and accurate way to test for the presence of T-cells against SARS-CoV-2. Currently, the available methods of measuring T-cell immunity require a blood draw from the test subject followed by the time-consuming and expensive analysis of the blood sample at specialized laboratories. BioVaxys' diagnostic includes a way to digitally measure T-cell presence via a smartphone (through the magnitude of the skin response which is a hallmark of DTH) so results can be sent immediately to healthcare providers. At this time, future studies and experiments are required to demonstrate that DTH from protein skin prick correlates to T-cell immunity in the blood against SARS-CoV-2. Now that the provisional patent application has been filed, BioVaxys intends to begin its studies, leveraging the planned work in Q1 2021 related to the manufacturing and clinical development of BVX-0320, BioVaxys's preclinical vaccine candidate for SARS-CoV-2, as it is anticipated that BioVaxys will initially investigate the use of the same GMP-compliant protein for the DTH diagnostic that is used in the manufacturing of BVX-0320.

David Berd, M.D., Chief Medical Officer at BioVaxys, who initially studied the potential use of DTH as a surrogate marker of T cell immunity in the context of clinical investigation of therapeutic autologous haptenized cancer vaccines[3], stated, "The availability of a low-cost and simple diagnostic for T-cell immunity would represent a critical tool for public health authorities to identify safe and at-risk populations and may contribute to worldwide efforts to combat COVID-19. BioVaxys believes that its novel T-cell diagnostic also provides an effective and low-cost tool to evaluate the effectiveness of any SARS-CoV-2 vaccine candidate in stimulating T cell immunity."[3]

Recent peer-reviewed studies, including one in Nature[4] and Cell[5], have highlighted the potential importance of T-cell, in addition to antibodies, when it comes to evaluating long-term immunity in patients who have recovered from COVID-19. While further evaluation is necessary, exploring this part of the immune system's response to prevent future infection will be necessary in the global fight against this disease.

BioVaxys' CEO, James Passin stated, "We are thrilled to further develop and move our novel diagnostic for SARS-CoV-2 T-cell immunity towards commercialization. The mass availability of our low cost and easy-to-administer T-cell immunity diagnostic could help to complement antibody testing and various public health risk mitigation strategies."

A provisional patent application offers a patent applicant an option of filing without including a formal patent claim. In BioVaxys's case, however, numerous patent claims have been included in the Provisional Application. The aim of a provisional patent application is to establish an early effective filing date, in addition to allowing the patent applicant to ascribe the phrase "patent pending" to any commercial products, methods, or services contemplated by the subject matter claimed. BioVaxys also plans to pursue an international Patent Cooperation Treaty (PCT) application, from which national stage patent applications can be submitted in both industrial jurisdictions and developing countries around the world.

Additional Information:
– BioVaxys' patent application is for a diagnostic tool to test for SARS-COV-2, and not for a therapeutic treatment of SARS-COV-2. In addition, BioVaxys intends to seek future clearance from the U.S. Food & Drug Administration after sufficient clinical tests can be evaluated.
– BioVaxys makes no express or implied claims that it has developed a vaccine to treat COVID-19 (or SARS-2 Coronavirus) at this time.

David Berd, M.D. the Chief Medical Officer of BioVaxys, has reviewed and approved the scientific disclosure contained in this press release. Dr. Berd is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. Dr. Berd received his BS from Pennsylvania State University and his MD from Jefferson Medical College of Thomas Jefferson University.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms for SARS-CoV-2 and various cancers. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell therapy used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and a patent application for its SARS-CoV-2 (Covid-19) technology. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FSE: 5LB).

ON BEHALF OF THE BOARD
Signed "James Pas
James Passin, CEO
+1 646 452 7054
jpassin@biovaxys.com

Media Contacts
Andrea Vuturo
+1 508 301 3774
biovaxys@dittopr.co

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the success and ultimate commercialization of its diagnostic test for T-cell immunity. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and commercializing its diagnostic test for T-cell immunity and the issuance of a patent for such technology, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that such diagnostic testing will not prove to be effective and/or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new diagnostic tests for marketing approval and, if so, whether the technology will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

[1] Immunology and Allergy Clinics of North America; Volume 21, Issue 2, 1 May 2001, Pages 383-397
[2] M. tuberculosis-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. H M Vordermeier 1, D P Harris, P K Mehrotra, E Roman, A Elsaghier, C Moreno, J Ivanyi. Scandavian Journal of Immunology 1992 Jun;35(6):711-8.
[3] BERD D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ: Immunopharmacological analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol., 22:403-415, 2004.
[4] Le Bert, N., Tan, A.T., Kunasegaran, K. et al. (2020). "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls." Nature 584:457-462, 2020
[5] Sekine, T., et al. (2020). "Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19." Cell 183: 158-163

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67255

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com